Meeting
2019 Gastrointestinal Cancers Symposium
A phase II, open-label pilot study evaluating the safety and activity of nal-IRI in combination with 5-FU and oxaliplatin in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study).
Authors
Hiral D. Parekh
University of Florida Health Cancer Center, Gainesville, FL
Hiral D. Parekh , David L. DeRemer , Kathryn Hitchcock , Susan P. McGorray , Allison Allegra , Alisha Daniels , Z. Hugh Fan , Carmen Joseph Allegra , Robert Zlotecki , Steven J. Hughes , Jessica L Cioffi , Jose Gilberto Trevino , Thomas J. George
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT03483038
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr TPS476)
DOI
10.1200/JCO.2019.37.4_suppl.TPS476
Abstract #
TPS476
Poster Bd #
Q15
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study.
First Author: Sherise C. Rogers
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study).
First Author: Sherise C. Rogers
Poster
2016 Gastrointestinal Cancers Symposium
A randomized, open-label phase II study of nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (mPAC).
First Author: Andrew Dean
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Results of a phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study).
First Author: Thomas J. George